Moody's affirms Pfizer

Moody's Investors Service said it affirmed the Aaa/Prime-1 ratings of Pfizer Inc., following the company's first quarter 2006 earnings release and share purchase announcement.

The outlook remains negative.

Moody's said the affirmation of Pfizer's Aaa ratings reflects the company's excellent credit profile based on the criteria outlined in Moody's global pharmaceutical rating methodology, including its impressive-scale and market positions, its high profit margins and return, its strong cash coverage of debt, its strong product pipeline and its low exposure to legal contingencies relative to its equity base.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.